Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Sunitinib malate

Base Information Edit
  • Chemical Name:Sunitinib malate
  • CAS No.:341031-54-7
  • Molecular Formula:C22H27FN4O2.C4H6O5
  • Molecular Weight:532.569
  • Hs Code.:29337900
  • European Community (EC) Number:638-825-9
  • NSC Number:736511
  • UNII:LVX8N1UT73
  • DSSTox Substance ID:DTXSID4046492
  • Wikidata:Q27283213
  • NCI Thesaurus Code:C26673
  • RXCUI:616275
  • Pharos Ligand ID:T16444CNC2AA
  • ChEMBL ID:CHEMBL1567
  • Mol file:341031-54-7.mol
Sunitinib malate

Synonyms:5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide;SU 011248;SU 11248;SU-011248;SU-11248;SU011248;SU11248;sunitinib;sunitinib malate;Sutent

Suppliers and Price of Sunitinib malate
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Usbiological
  • Sunitinib Malate
  • 10mg
  • $ 368.00
  • Tocris
  • Sunitinib malate ≥99%(HPLC)
  • 50
  • $ 1001.00
  • Sigma-Aldrich
  • Sunitinib malate ≥98% (HPLC)
  • 5mg
  • $ 121.00
  • Sigma-Aldrich
  • Sunitinib malate ≥98% (HPLC)
  • 25mg
  • $ 477.00
  • Medical Isotopes, Inc.
  • Sunitinib malate >98%
  • 25 mg
  • $ 1200.00
  • Matrix Scientific
  • (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate 95%
  • 5g
  • $ 1573.00
  • Matrix Scientific
  • (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate 95%
  • 1g
  • $ 740.00
  • DC Chemicals
  • Sunitinib malate >98%
  • 100 mg
  • $ 200.00
  • CSNpharm
  • Sunitinib malate
  • 100mg
  • $ 51.00
  • Crysdot
  • Sunitinib malate 98+%
  • 5g
  • $ 318.00
Total 217 raw suppliers
Chemical Property of Sunitinib malate Edit
Chemical Property:
  • Melting Point:189-191°C 
  • Boiling Point:572.1 °C at 760 mmHg 
  • Flash Point:299.8 °C 
  • PSA:172.06000 
  • Density:1.3600g/mLat 25°C(lit.) 
  • LogP:2.77040 
  • Storage Temp.:Store at +4°C 
  • Solubility.:DMSO: >10mg/mL 
  • Hydrogen Bond Donor Count:6
  • Hydrogen Bond Acceptor Count:9
  • Rotatable Bond Count:10
  • Exact Mass:532.23332757
  • Heavy Atom Count:38
  • Complexity:765
Purity/Quality:

99% *data from raw suppliers

Sunitinib Malate *data from reagent suppliers

Safty Information:
  • Pictogram(s):
  • Hazard Codes:
  • Statements: 61-2-48/25-36/37-22-53 
  • Safety Statements: 53-22-36/37-24/25 
MSDS Files:

SDS file from LookChem

Useful:
  • Canonical SMILES:CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
  • Isomeric SMILES:CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O
  • Recent ClinicalTrials:Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • Recent EU Clinical Trials:A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
  • Uses Anti-cancer drugs Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
  • Description Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3. It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src. Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively). It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day. Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Technology Process of Sunitinib malate

There total 32 articles about Sunitinib malate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
In methanol; ethanol; at 20 ℃; for 2h; Darkness;
Refernces Edit
Post RFQ for Price